

Virax Biolabs Group Limited
20 North Audley Street
London, W1K 6LX
United Kingdom

VIA EDGAR

March 28, 2023

U.S. Securities & Exchange Commission
Office of Life Sciences
Division of Corporation Finance
100 F Street, NE
Attn: Lauren Hamill

Re: Virax Biolabs Group Limited
Registration Statement on Form F-1
Filed March 22, 2023
File No. 333-270734

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Virax Biolabs Group Limited hereby requests acceleration of effectiveness of the above referenced Registration Statement so that it will become effective at 5:00 p.m., Eastern Time, on March 30, 2023, or as soon as thereafter practicable.

Very truly yours,

/s/ James Foster

James Foster
Chief Executive Officer

